NCT04178447已完成1 期
An Open-label, Multi-center Trial to Evaluate the Pharmacokinetic Profile of Glepaglutide After a Single Subcutaneous Injection in Subjects With Varying Degrees of Renal Function
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 3
- 主要终点
- Pharmacokinetic Variables
研究概览
简要总结
This is two stage design, open-label, multi-center, non-randomized trial evaluating the PK of a single, subcutaneous dose of 10 mg glepaglutide in subjects with varying degrees of renal function. The renal function will be calculated by the estimated glomerular filtration rate (eGFR) according to the Modification of Diet in Renal Disease (MDRD) equation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •All subjects
- •Able to understand and willing to sign the informed consent
- •eGFR values as defined in in the arms
- •Willing and able to comply with the study requirements
- •Male and female subjects age 18 to 70 years (both inclusive) at the time of informed consent
- •BMI 20.0 - 30.0 kg/m2 both inclusive
- •Must be willing to comply with the contraception, sperm-donation requirements, and study restrictions.
- •Renally Impaired Subjects (in Addition)
- •Subject has a stable disease, including disease(s) associated with renal impairment, under medical control (ie, no changes in medication within 30 days prior to study drug administration). Stable renal impairment, defined as no clinically significant change in disease status within 3 months before screening.
排除标准
- •All Subjects
- •Suspicion of hypersensitivity, intolerance, or allergy to glepaglutide
- •History of alcohol or drug abuse
- •Clinically relevant abnormal medical history, abnormal findings on physical examination, vital signs, clinically significant abnormalities on 12-lead ECG, or laboratory tests at Screening that the Investigator judges as likely to interfere with the objectives of the study or the safety of the subject except for conditions associated with renal impairment in subjects with renal impairment
- •Uncontrolled treated/untreated hypertension (defined as a mean of 3 repeated measurements for systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 110 mmHg); current or documented history of repeated clinically significant hypotension or severe episodes of orthostatic hypotension (systolic blood pressure < 90 mmHg and/or diastolic blood pressure < 50 mmHg)
- •Acute illness within 14 days prior to dosing unless mild in severity and approved by the Investigator and Sponsor's medical representative
- •Presence of active infection requiring antibiotics. Ingestion of alcohol within 72 hours prior to study drug administration and during PK sampling period including Follow-Up
- •Participation in another investigational drug study within 30 days prior to study drug administration or exposure to more than three new investigational agents within 12 months prior to study drug administration
- •Previous exposure to GLP-1, GLP-2, human growth hormone, somatostatin, or analogues thereof within 3 months prior to Screening. Use of dipeptidyl peptidase-4 inhibitors within 3 months prior to Screening
- •Previous exposure to glepaglutide
- •Donation or loss of more than 450 mL blood during the 3 months before the start of Screening
- •Female subjects who are breastfeeding, pregnant, or planning to become pregnant during the study
- •Positive serology for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti-HCV) or human immunodeficiency virus antibodies (anti-HIV)-1/2, unless the absence of an active hepatitis B/C infection is confirmed by a polymerase chain reaction (PCR) test, at Screening
- •Positive urine screen of drugs of abuse (if not due to concomitant medication) or alcohol breath test at Screening and/or Day -1
- •Legal incapacity or limited legal capacity
- •Renally Impaired Subjects (in Addition)
- •Acute renal failure (as judged by the Investigator)
- •Renal impairment requiring dialysis
- •History of kidney transplant regardless of functionality
- •Serum albumin concentration <25 g/L
- •Haemoglobin concentration <100 g/L
- •Medications known to affect the elimination of serum creatinine (e.g., trimethoprim or cimetidine) and competitors of renal tubular secretion (e.g., probenecid) within 60 days prior to study drug administration
- •Subjects With Normal Renal Function (in Addition)
- •Significant medical history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, haematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator -
研究组 & 干预措施
Group 3: moderate RI
Experimental
subjects with eGFR 30 to <60 mL/min/1.73 m2
干预措施: Glepaglutide (Drug)
Group 2: normal renal function
Experimental
subjects with eGFR ≥90 mL/min/1.73 m2
干预措施: Glepaglutide (Drug)
Group 1: ESRD subjects not on dialysis or severe RI
Experimental
subjects with eGFR <15 mL/min/1.73 m2) or (eGFR 15 to <30 mL/min/1.73 m2)
干预措施: Glepaglutide (Drug)
Group 4: mild RI
Experimental
subjects with eGFR 60 to <90 mL/min/1.73 m2
干预措施: Glepaglutide (Drug)
结局指标
主要结局
Pharmacokinetic Variables
时间窗: 11 days
AUC0-168 area under the concentration-time curve (AUC) from time 0 to 168 hours Cmax maximum observed plasma concentration
次要结局
- Safety Variables(11 days)
研究者
研究点 (3)
Loading locations...
相似试验
撤回
4 期
Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.Chronic Myeloid Leukemia (CML)NCT01605981Novartis Pharmaceuticals
已完成
2 期
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell CarcinomaHNSCCLip SCCOral Cavity CancerOropharynx CancerLarynx CancerHypopharynx CancerNasopharynx CancerCutaneous Squamous Cell CarcinomaHead and Neck NeoplasmsHead and Neck CancerHead and Neck Squamous Cell CarcinomaSinonasal CarcinomaNCT03082534University of California, San Diego78
已完成
1 期
Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent PatientsBacterial InfectionNCT01156077Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)20
已完成
2 期
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial CancerSolid Tumors and Advanced Endometrial CancerEndometrial CancerSecond-line TreatmentVEGFNCT01379534Novartis Pharmaceuticals53
已完成
2 期
PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's LymphomaHodgkin Lymphoma, AdultNCT03155425Jiangsu HengRui Medicine Co., Ltd.75